References

Barker J, Hoffmann M, Wozel G Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011; 165:(5)1109-17 https://doi.org/10.1111/j.1365-2133.2011.10615.x

Basavaraj KH, Navya MA, Rashmi R Stress and quality of life in psoriasis: an update. Int J Dermatol. 2011; 50:(7)783-92 https://doi.org/10.1111/j.1365-4632.2010.04844.x

Devaux S, Castela A, Archier E Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012; 26:61-7 https://doi.org/10.1111/j.1468-3083.2012.04525.x

Gelfand JM, Wan J, Callis Duffin K Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe psoriasis in the clinical practice setting. Arch Dermatol. 2012; 148:(4)487-94 https://doi.org/10.1001/archdermatol.2012.370

Ghazizadeh R, Shimizu H, Tosa M, Ghaizadeh M Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci. 2010; 7:(5)284-9 https://doi.org/10.7150/ijms.7.284

Ghazizadeh R, Tosa M, Ghazizadeh M Clinical improvement in psoriasis with treatment of associated hyperlipidaemia. Am J Med Sci. 2011; 341:(5)394-8 https://doi.org/10.1097/MAJ.0b013e3181ff8eeb

Gould BE, Dyer RM, 4th edn. St Louis, MO: Elsevier; 2011

Hugh J, Van Voorhees AS2, Nijhawan RI From the medical board of the national psoriasis foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol. 2014; 70:(1)168-77 https://doi.org/10.1016/j.jaad.2013.09.020

Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M Psoriasis: is the impairment to a patient’s life cumulative?. J Eur Acad Dermatol Venereol. 2010; 24:(9)989-1004 https://doi.org/10.1111/j.1468-3083.2010.03705.x

Kragballe K, Menter A, Lebwohl M Long-term management of scalp psoriasis: perspectives from the International psoriasis council. J Dermatolog Treat. 2013; 24:(3)188-92 https://doi.org/10.3109/09546634.2012.681017

Kurian A, Barankin B Current effective topical therapies in the management of psoriasis. Skin Therapy Lett. 2011; 16:(1)4-7

Maradit-Kremers H, Dierkhising RA, Crawson CS, Icen M, Ernste F, McEvoy MT Risk and predictors of cardiovascular disease in psoriasis: a population-based study. Int J Dermatol. 2012; 52:(1)32-40 https://doi.org/10.1111/j.1365-4632.2011.05430.x

Mason AR, Mason J, Cork M, Dooley G, Hancock H Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013; 3 https://doi.org/10.1002/14651858.CD005028.pub3

Mattei PL, Corey KC, Kimball AB Psoriasis area severity index and the dermatology life quality index: the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2013; 28:(3)333-7 https://doi.org/10.1111/jdv.12106

Menter A, Korman NJ, Elmets CA Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009; 61:(3)451-85 https://doi.org/10.1016/j.jaad.2009.03.027

Mrowietz U, Kragballe K, Reich K Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011; 303:(1)1-10 https://doi.org/10.1007/s00403-010-1080-1

Mudiganda T, Dabade TS, Feldman SR A review of targeted Ultraviolet B phototherapy for psoriasis. J Am Acad Dermatol. 2011; 66:(4)664-72 https://doi.org/10.1016/j.jaad.2011.07.011

Murphy G, Reich K In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol. 2011; 25:3-8 https://doi.org/10.1111/j.1468-3083.2011.04059.x

London: NICE; 2012

Navinni AA, Poulin Y, Menter A, Gu Y, Teiveira HD Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate to severe psoriasis. J Drugs Dermatol. 2014; 13:(5)554-62

Parsi KK, Brezinski EA, Lin TC, Li CS, Armstrong AW Are patients with psoriasis being screened for cardiovascular disease risk factors? A study of screening practices and awareness among primary care physicans and cardiologists. J Am Acad Dermatol. 2012; 67:(3)357-62 https://doi.org/10.1016/j.jaad.2011.09.006

Rácz E, Prens EP, Kurek D Effective treatment of psoriasis with narrow band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol. 2011; 131:(7)1547-58 https://doi.org/10.1038/jid.2011.53

Raychaudhuri SP A cutting edge overview: psoriatic disease. Clin Rev Allergy Immunol. 2013; 44:(2)109-13 https://doi.org/10.1007/s12016-012-8309-z

Reich K, Burden AD, Eaton JN, Hawkins NS Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta analysis of randomised controlled trials. Br J Dermatol. 2012; 166:(1)179-88 https://doi.org/10.1111/j.1365-2133.2011.10583.x

Saurat JH, Stingl G, Dubertret L Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008; 158:(3)558-66 https://doi.org/10.1111/j.1365-2133.2007.08315.x

Sawyer L, Samarasekera EJ, Wonderling D, Smith CH Topical therapies for the treatment of localised psoriasis in primary care: a cost effectiveness analysis. Br J Dermatol. 2013; 168:(5)1095-105 https://doi.org/10.1111/bjd.12261

Sawyer LM, Wonderling D, Jackson K, Murphy R, Samarasekera EJ, Smith CH Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost effectiveness analysis. Pharmacoeconomics. 2014; 33:(2)163-77 https://doi.org/10.1007/s40273-014-0226-y

Zhou Q, Mrowietz U, Rostami-Yazdi M Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med. 2009; 47:(7)891-905 https://doi.org/10.1016/j.freeradbiomed.2009.06.033

A critical appraisal of the assessment and management of psoriasis

02 February 2016
Volume 8 · Issue 2

Abstract

Psoriasis affects a substantial number of the UK population. The chronic inflammatory skin disease that typically follows a relapsing and remitting course, resulting from the abnormal activation of T cells and associated increase in cytokines in affected tissues, can transpire at any age (Gould and Dyer, 2011). Plaque psoriasis is by far the most common type of the disease making up 90% of all cases and can result in all of functional, psychological and social morbidity (Basavaraj et al, 2011). Moreover, psoriasis has been linked with an increased risk of developing cardiovascular disease. There are a considerable amount of treatment options available for psoriasis, resulting in variance in practice within primary care, particularly concerning when to refer, drug monitoring and psychological support (Murphy and Reich, 2011). This is important to recognise within the paramedic profession as there is now an increased responsibility for paramedics to discharge patients within their own home and/or refer when necessary and safe to do so. Moreover, there is minimal knowledge on dermatology in the paramedic profession, further fortifying the importance of learning about the best treatment option for psoriasis. A stepwise approach to treatment is recommended, dependent on the severity of the disease (National Institute for Health and Care Excellence, 2012).

Psoriasis is estimated to affect around 2.2% of the UK population and can transpire at any age; therefore, identifying the most effective treatment for the disease is paramount (National Institute for Health and Care Excellence (NICE), 2012). This article will endeavour to demonstrate strategic awareness of the policy drivers within health care and current legislature that have influenced the decisions on the treatment of psoriasis. With the growing responsibility for paramedics to discharge on scene, the increasing volume of primary care type calls to the ambulance service, and the minimal amount taught to undergraduate paramedics concerning dermatology, there is a greater need for rashes to be recognised in the pre-hospital setting. In particular, knowing when referral is necessary and how quickly this is required. Furthermore, for many people, psoriasis can result in functional, psychological and social morbidity, consequently having a huge impact on daily life (Basavaraj et al, 2011). This suggests the importance of determining which treatment option is best, although this can be extremely difficult. Additionally, one study has reported that individuals who suffer with severe psoriasis are at an increased risk of developing cardiovascular disease from the age of 20 years, further fortifying the need for adequate treatment (Parsi et al, 2012).

Subscribe to get full access to the Journal of Paramedic Practice

Thank you for visiting the Journal of Paramedic Practice and reading our archive of expert clinical content. If you would like to read more from the only journal dedicated to those working in emergency care, you can start your subscription today for just £48.

What's included

  • CPD Focus

  • Develop your career

  • Stay informed